Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain

European Journal of Pharmacology

Volumn 612, Issue 1-3, 2009, Pages 54-60

  Guo, Jian You ^a   Li, Chang Yu ^b   Ruan, Ye Ping ^b   Sun, Meng ^a   Qi, Xiao Li ^a   Zhao, Bao Sheng ^c   Luo, Fei ^a  

^a INSTITUTE OF PSYCHOLOGY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Celecoxib; Chronic unpredictable stress; Cyclooxygenase 2; Depressive like behavior; Prostaglandin E2

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; LONG TERM CARE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STRESS;

ANIMALS; BRAIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DEPRESSIVE DISORDER; GENE EXPRESSION; MALE; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TIME FACTORS;

EID: 65549129726     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.076     Document Type: Article

References (40)

1. Anisman H., and Matheson K. Stress, depression, and anhedonia: caveats concerning animal models. Neurosci. Biobehav. Rev. 29 (2005) 525-546
2. Barrios-Rodiles M., Keller K., Belley A., and Chadee K. Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Biochem. Biophys. Res. Commun. 225 (1996) 896-900
3. Bosetti F., Rintala J., Seemann R., Rosenberger T.A., Contreras M.A., Rapoport S.I., and Chang M.C. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol. Psychiatry 7 (2002) 845-850
4. Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., Kriwin P., and Mendlewicz J. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int. Clin. Psychopharmacol. 21 (2006) 219-225
5. Cassano P., Hidalgo A., Burgos V., Adris S., and Argibay P. Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression. Pharmacogenomics J. 6 (2006) 381-387
6. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., and Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008) 45-46
7. D'Aquila P.S., Peana A.T., Carboni V., and Serra G. Different effects of desipramine on locomotor activity in quinpirole-treated rats after repeated restraint and chronic mild stress. J. Psychopharmacol. 14 (2000) 347-352
8. Dembo G., Park S.B., and Kharasch E.D. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 102 (2005) 409-415
9. Guo J.Y., Huo H.R., Yang Y.X., Li C.H., Liu H.B., Zhao B.S., Li L.F., Ma Y.Y., Guo S.Y., and Jiang T.L. 2-methoxycinnamaldehyde reduces IL-1beta-induced prostaglandin production in rat cerebral endothelial cells. Biol. Pharm. Bull. 29 (2006) 2214-2221
10. Guo J.Y., Huo H.R., Zhao B.S., Liu H.B., Li L.F., Ma Y.Y., Guo S.Y., and Jiang T.L. Cinnamaldehyde reduces IL-1beta-induced cyclooxygenase-2 activity in rat cerebral microvascular endothelial cells. Eur. J. Pharmacol. 537 (2006) 174-180
11. Heine V.M., Maslam S., Zareno J., Joëls M., and Lucassen P.J. Suppressed proliferation and apoptotic changes in the rat dentate gyrus after acute and chronic stress are reversible. Eur. J. Neurosci. 19 (2004) 131-144
12. Herschman H.R. Prostaglandin synthase 2. Biochim. Biophys. Acta 1299 (1996) 125-140
13. Höcherl K., Wolf K., Castrop H., Ittner K.P., Bucher M., Kees F., Grobecker H.F., and Kurtz A. Renocortical expression of renin and of cyclooxygenase-2 in response to angiotensin II AT1 receptor blockade is closely coordinated but not causally linked. Pflugers Arch. 442 (2001) 821-827
14. Horrobin D.F., Mtabaji J.P., Manku M.S., and Karmazyn M. Lithium as aregulator of hormone-stimulated prostaglandin synthesis. In: Johnson F.N., and Johnson S. (Eds). Lithium in Medical Practice (1978), University Park Press, Baltimore
15. Katz R.J. Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol. Biochem. Behav. 16 (1982) 965-968
16. Lee H.J., Ertley R.N., Rapoport S.I., Bazinet R.P., and Rao J.S. Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochem. Res. 33 (2008) 861-866
17. Lieb J., Karmali R., and Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot. Med. 10 (1983) 361-367
18. Lukiw W.J., and Bazan N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 50 (1997) 937-945
19. Madrigal J.L., Hurtodo O., Moro M.A., Lizasoian I., Lorenzo P., Castrillo A., Bosca L., and Leza J.C. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. Neuropsychopharmacology 26 (2002) 155-163
20. Madrigal J.L., Moro M.A., Lizasoain I., Lorenzo P., Ferna′ndez A.P., Rodrigo J., Bosca′ L., and Leza J.C. Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain. Neuropsychopharmacology 28 (2003) 1579-1588
21. Matthews K., Forbes N., and Reid I.C. Sucrose consumption as a hedonic measure following chronic unpredictable mild stress. Physiol. Behav. 57 (1995) 241-248
22. McArthur R., and Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol. Biochem. Behav. 84 (2006) 436-452
23. McNally L., Bhagwagar Z., and Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr. 13 (2008) 501-510
24. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., and Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11 (2006) 680-684
25. Myint A.M., Steinbusch H.W., Goeghegan L., Luchtman D., Kim Y.K., and Leonard B.E. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 14 (2007) 65-71
26. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., Bowden C.L., and Soares J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 23 (2008) 87-94
27. Okumura T., Murata Y., Hizue M., Matsuura T., Naganeo R., Kanai T., Murase A., Sakakibara A., Fujita I., and Nakao K. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor. Eur. J. Pharmacol. 539 (2006) 125-130
28. Pace T.W., Hu F., and Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behabv. Immun. 21 (2007) 9-19
29. Powell W.S. Reversed-phase high-pressure liquid chromatography of arachidonic acid metabolites formed by cyclooxygenase and lipoxygenases. Anal. Biochem. 148 (1985) 59-69
30. Raison C.L., Capuron L., and Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends. Immunol. 27 (2006) 24-31
31. Rapoport S.I., and Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch. Gen. Psychiatry 59 (2002) 592-596
32. Rygula R., Abumaria N., Flugge G., Fuchs E., Ruther E., and Havemann-Reinecke U. Anhedonia and motivational deficits in rats: impact of chronic social stress. Behav. Brain Res. 162 (2005) 127-134
33. Singal A., Tirkey N., and Chopra K. Reversal of LPS-induced immobility in mice by green tea polyphenols: possible COX-2 mechanism. Phytother. Res. 18 (2004) 723-728
34. Song C., and Leonard B. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 29 (2005) 627-647
35. Willner P. Validity, reliability and utility of the chronic mild stress model of depression a 10-year review and evaluation. Psychopharmacology 134 (1997) 319-329
36. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52 (2005) 90-110
37. Willner P., Towell A., Sampson D., Sophokleous S., and Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 93 (1987) 358-364
38. Wu K.K., Sanduja R., Tsai A.L., Ferhanoglu B., and Loose-Mitchell D.S. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc. Natl. Acad. Sci. USA. 88 (1991) 2384-2387
39. Zhang G.S., Liu D.S., Dai C.W., and Li R.J. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am. J. Hematol. 81 (2006) 242-255
40. Zyglewska T., Sanduja R., Ohashi K., Loose-Mitchell D.S., Sanduja S.K., and Wu K.K. Inhibition of endothelial cell prostaglandin H synthase gene expression by naproxen. Biochim. Biophys. Acta. 1131 (1992) 78-82